Default company panoramic image
St 002 high resolution

Siamab Therapeutics, Inc.

Siamab develops drugs targeting cancers expressing abnormal carbohydrates (glycans) including ovarian, pancreatic, prostate, and other solid tumors.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Newton, MA, US
  • Currency USD
  • Founded January 2006
  • Employees 4
  • Website siamab.com

Company Summary

Siamab develops therapies targeting cancers that express abnormal carbohydrates (glycans) including ovarian, pancreatic, prostate, colon, breast and other solid tumors. These cancer specific antigens (TACAs) suppress immune function, provide resistance to chemotherapy, and enable tissue invasion and metastasis. Siamab's platform enables the rapid creation of multiple antibodies to these challenging targets.

Team

  • Default avatar
    Jeff Behrens
    President and CEO

    Jeff worked formerly at Edimer (funded by Third Rock), Alnylam, and Biogen. He was the founder/CEO of The Telluride Group, sold to mindSHIFT Technologies (funded by Fidelity.) Jeff completed his MBA @ MIT-Sloan and his MS @ The Harvard-MIT Division of Health Sciences and Technology.

Advisors

  • Default avatar
    Joseph Faber
    Lawyer
    Unconfirmed
    Default avatar
    Jeff Solomon
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Mass Medic Angels
    Unconfirmed
    Default avatar
    Boston Harbor Angels
    Unconfirmed
    Default avatar
    Launchpad Angels
    Unconfirmed